Rig is a novel Ras-related protein and potential neural tumor suppressor

被引:48
作者
Ellis, CA
Vos, MD
Howell, H
Vallecorsa, T
Fults, DW
Clark, GJ
机构
[1] NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA
[2] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84132 USA
[3] Huntsman Canc Inst, Salt Lake City, UT 84132 USA
关键词
D O I
10.1073/pnas.142193799
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The Ras superfamily consists of a large group of monomeric GTPases demonstrating homology to Ras oncoproteins. Although structurally similar, Ras-superfamily proteins are functionally diverse. Whereas some members exhibit oncogenic properties, others may serve as tumor suppressors. We have identified a novel Ras-related protein that suppresses cell growth and have designated it Rig (Ras-related inhibitor of cell growth). Overexpression of Rig inhibited Ras-mediated cellular transformation and activation of downstream signaling in NIH 3T3 cells. rig mRNA is expressed at high levels in normal cardiac and neural tissue. However, Rig protein expression is frequently lost or down-regulated in neural tumor-derived cell lines and primary human neural tumors. Moreover, expression of exogenous Rig in human astrocytoma cells suppressed growth. Rig has a C-terminal CAAX motif that codes for posttranslational modification by both farnesyl and geranylgeranyl isoprenoid lipids. Consequently, Rig may play a role in the cellular response to farnesyl transferase inhibitors. Rig bears 63% overall sequence homology to a recently described Ras-family member Noey2, a tumor suppressor in breast and ovarian tissue. Therefore, Rig and Noey2 may represent a new subfamily of Ras-like tumor suppressors.
引用
收藏
页码:9876 / 9881
页数:6
相关论文
共 45 条
  • [11] Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W
  • [12] Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis
    Dal Canto, RA
    Shaw, MK
    Nolan, GP
    Steinman, L
    Fathman, CG
    [J]. CLINICAL IMMUNOLOGY, 1999, 90 (01) : 10 - 14
  • [13] Du W, 1999, CANCER RES, V59, P5492
  • [14] INHIBITION OF NIH-3T3 CELL-PROLIFERATION BY A MUTANT RAS PROTEIN WITH PREFERENTIAL AFFINITY FOR GDP
    FEIG, LA
    COOPER, GM
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (08) : 3235 - 3243
  • [15] Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3
  • [16] Fu HW, 1999, RECENT PROG HORM RES, V54, P315
  • [17] Farnesyltransferase inhibitors versus Ras inhibitors
    Gibbs, JB
    Graham, SL
    Hartman, GD
    Koblan, KS
    Kohl, NE
    Omer, CA
    Oliff, A
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 1997, 1 (02) : 197 - 203
  • [18] Farnesyltransferase inhibitors and anti-Ras therapy
    Gibbs, JB
    Kohl, NE
    Koblan, KS
    Omer, CA
    SeppLorenzino, L
    Rosen, N
    Anthony, NJ
    Conner, MW
    deSolms, SJ
    Williams, TM
    Graham, SL
    Hartman, GD
    Oliff, A
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) : 75 - 83
  • [19] FARNESYLTRANSFERASE INHIBITORS - RAS RESEARCH YIELDS A POTENTIAL CANCER THERAPEUTIC
    GIBBS, JB
    OLIFF, A
    KOHL, NE
    [J]. CELL, 1994, 77 (02) : 175 - 178
  • [20] BENZODIAZEPINE PEPTIDOMIMETICS - POTENT INHIBITORS OF RAS FARNESYLATION IN ANIMAL-CELLS
    JAMES, GL
    GOLDSTEIN, JL
    BROWN, MS
    RAWSON, TE
    SOMERS, TC
    MCDOWELL, RS
    CROWLEY, CW
    LUCAS, BK
    LEVINSON, AD
    MARSTERS, JC
    [J]. SCIENCE, 1993, 260 (5116) : 1937 - 1942